Health care reform and the pharmaceutical industry: Crucial decisions are expected

Health Care Manager

Volumn 20, Issue 3, 2002, Pages 22-32

  Liberman, Aaron ^a   Rubinstein, Jason ^a  

^a UNIVERSITY OF CENTRAL FLORIDA   (United States)

Author keywords

Health care costs; Pharmaceutical reform; Social insurance; Wonder drugs

Indexed keywords

GENERIC DRUG;

ADVERTIZING; AGED; ARTICLE; DRUG COST; DRUG INDUSTRY; ECONOMICS; FINANCIAL MANAGEMENT; HEALTH CARE POLICY; HEALTH INSURANCE; HEALTH MAINTENANCE ORGANIZATION; HUMAN; LEGAL ASPECT; MEDICAID; MEDICARE; ORGANIZATION AND MANAGEMENT; POPULATION DYNAMICS; REIMBURSEMENT; UNITED STATES;

ADVERTISING; AGED; DRUG COSTS; DRUG INDUSTRY; DRUGS, GENERIC; FINANCING, PERSONAL; HEALTH CARE REFORM; HEALTH MAINTENANCE ORGANIZATIONS; HEALTH POLICY; HUMANS; INSURANCE, MEDIGAP; MEDICAID; MEDICARE; MEDICARE PART C; POPULATION DYNAMICS; REIMBURSEMENT MECHANISMS; UNITED STATES;

EID: 0036516323     PISSN: 15255794     EISSN: 1550512X     Source Type: Journal    
DOI: 10.1097/00126450-200203000-00004     Document Type: Article

References (29)

1. E.M. Kolassa, Elements of Pharmaceutical Pricing (New York/London: Haworth Press, 1997).
2. “Healthcare Spending to Top $2 Trillion Next Decade, says HCFA.” (July 15, 1999). http://www.devicelink.com/news/99/7/10673.html (Accessed 9 May 2000).
3. B. Gage, “The History and Growth of Medicare Managed Care. (Managed Care and Older People: Issues and Experiences),” Generations 22, no. 8 (Summer 1998): 11.
4. M. Moon, “Growth in Medicare Spending: What will Beneficiaries Pay?”(May 1999). http://www.cmwf.org/programs/medfutur/Moon_growth_318.asp (Accessed 9 May 2000).
5. A. Levin, “Prescription Drug Prices Soar,” Health Facts 4(1).
6. M. Gluck, “A Medicare Prescription Drug Benefit.” (April 1999). http://www.nasi.org/Medicare/Briefs/medbr1.htm (Accessed 8 May 2000).
7. M. Waid, “Brief Summaries of Medicare & Medicaid.” (June 25, 1999). http://www.hcfa.gov/medicare/ormedmed.htm (Accessed 9 May 2000).
8. T. Riley, “State’s Perspective on Managed Care for the Elderly. (Managed Care and Older People Issues and Experiences),” Generations 22, no. 2 (Summer 1995): 69(5).
9. M. Serafini, “Another Looming Crisis. (Medicaid),” National Journal, (January 2, 1999): 32.
10. R. Cauchi, “Making Medicines Affordable,” State Legislatures 25, no. 10 (December 1999): 10.
11. T. Brock, “Medicare+ Choice Creates Opportunities for PSOs,” Healthcare Financial Management 52, no. 3 (March 1998): 48(4).
12. J. Worsham, “Pharmaceuticals Present a Paradox.(rising prices reflect cost of drug research),” Nation’s Business 87, no. 2 (February 1999): 52(1).
13. R. Woosley, “A Prescription for Better Prescriptions. (prescription drugs and increased health care costs),” Issues in Sciences and Technology 10, no. 3 (Spring 1994): 59(8).
14. M. Serafini, “Bitter Pills. Medicare,” National Journal 30, no. 44 (31 October 1998): 2554(1).
15. M. Scheller, “Generics. (generic drugs),” Current Health 23, no. 4 (December 2, 1996): 30(2).
16. C. Warden, “The Prescription for High Drug Prices. (factors contributing to rising prescription prices),” Consumers’ Research Magazine 75, no. 12 (December 1992): 10(5).
17. J. Zoeller, “Generic Rates Rise.(pharmacists’ of generic drugs),” American Druggist 215, no. 9 (September 1998): 474.
18. “Pharmaceutical Research and Manufacturers of America: Prescription Medicines-Benefits and Costs.” (March 1, 1999). http://www.phrma.org/medicare/medicare7.html (Accessed 23 May 2000).
19. J. Wang, “Silent Too Long, the Pharmaceutical Industry Speaks Out,” Public Relations Journal 48, no. 3 (March 1992): 6(2).
20. C. Lindsay, The Pharmaceutical Industry (New York: Wiley Medical, 1978).
21. G. Safian, “Finding a New Marketing Rx for Pharmaceuticals,” Public Relations Journal 50, no. 3 (March 1994): 24(3).
22. C. Krol, “Database Marketing Proves Rx Value: Systems Detailing Patient History Improve Targeting, Cut Waste,” Advertising Age (March 15, 1999): S18(1).
23. M. Hollon, “Direct-to Consumer Marketing of Prescription Drugs: Creating Consumer Demand,” The Journal of the American Medical Association 281 (January 27, 1999): 4.
24. “Prescription for Profit: (Pharmaceutical companies market directly to consumers),” Advertising Age 69, no. 11 S1(2).
25. “DTC Drug Ad Spending Climbs 43% in 1st Half,” Advertising Age (October 18, 1999): 72.
26. D. Greenberg, “Drug Pricing “Power Keg” Stirs Up U.S. Health Care Politics,” The Lancet 355, no. 9198 (January 8, 2000): 125.
27. D. Cauchon, “Americans Pay More for Medicine,” USA Today (10 November 1999). http://www.usatoday.com/life/health/drugs/lhdru066.htm (Accessed 27 April 2000).
28. C. Gorman, “Border Bargains: to save on costly Pills. Americans go to Mexico and get them to less,” Time 147, no. 8 (February 19, 1996): 54(1).
29. R. Gundling, “Without Action, Prescription Benefit Could Bankrupt Medicare,” Healthcare Financial Management 55, no. 6 (June 2001): 86.